Avadel Pharmaceuticals Plc ADR (AVDL)

Jun 5, 2025, 7:30 AM EDT - 1 day ago

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

May 29, 2025, 4:05 PM EDT - 7 days ago

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

May 29, 2025, 8:00 AM EDT - 8 days ago

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 11:43 AM EDT - 22 days ago

Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

May 13, 2025, 4:15 PM EDT - 23 days ago

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

May 13, 2025, 8:00 AM EDT - 24 days ago

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 4:05 PM EDT - 4 weeks ago

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025, 12:45 PM EDT - 4 weeks ago

Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 4 weeks ago

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

May 6, 2025, 12:30 PM EDT - 4 weeks ago

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

Apr 30, 2025, 8:00 AM EDT - 5 weeks ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Apr 17, 2025, 8:00 AM EDT - 7 weeks ago

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

Apr 8, 2025, 1:30 PM EDT - 2 months ago

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 2 months ago

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

Mar 5, 2025, 8:00 AM EST - 3 months ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Mar 3, 2025, 11:53 PM EST - 3 months ago

Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:00 AM EST - 3 months ago

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:05 PM EST - 3 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

Feb 24, 2025, 8:00 AM EST - 3 months ago

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

Feb 11, 2025, 6:08 PM EST - 4 months ago

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 10, 2025, 9:00 AM EST - 4 months ago

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

Jan 13, 2025, 12:56 PM EST - 5 months ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI

Jan 12, 2025, 3:26 AM EST - 5 months ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 8, 2025, 4:15 PM EST - 5 months ago

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Jan 3, 2025, 8:00 AM EST - 5 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Nov 13, 2024, 8:00 AM EST - 7 months ago

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 3:19 PM EST - 7 months ago

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:00 AM EDT - 7 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

Oct 17, 2024, 10:03 AM EDT - 8 months ago

US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 9:41 AM EDT - 8 months ago

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Sep 3, 2024, 8:30 AM EDT - 9 months ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 3, 2024, 8:00 AM EDT - 9 months ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

Aug 9, 2024, 12:27 PM EDT - 10 months ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Avadel Pharmaceuticals to Join Russell 3000® Index

May 22, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

May 21, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Apr 2, 2024, 3:40 AM EDT - 1 year ago

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Mar 4, 2024, 3:37 PM EST - 1 year ago

Avadel Pharmaceuticals Issues Statement On Patent Litigation

Mar 4, 2024, 10:43 AM EST - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 6:30 AM EST - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 28, 2024, 2:56 AM EST - 1 year ago

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Jan 11, 2024, 11:31 AM EST - 1 year ago

Avadel May Continue To Outperform With Positive Launch Momentum

Nov 14, 2023, 4:00 PM EST - 1 year ago

Avadel: Lumryz Lights Up The Oxybate Market, Maintaining Buy Rating

Nov 8, 2023, 1:48 PM EST - 1 year ago

Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:00 AM EST - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 20, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023